Warning: The NCBI web site requires JavaScript to function. more...
Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing.
Coletta E, Coppolino S, Federico F, Fulia F.
Ital J Pediatr. 2010 Jul 7;36:48.
Related citations
Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.
J Manag Care Pharm. 2010 Jan-Feb;16(1):15-22.
Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA, Cosgrove JF, MacMahon P.
Ir Med J. 2000 Dec;93(9):284.
Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D, Cummins C, Bayliss S, Sandercock J, Burls A.
Health Technol Assess. 2008 Dec;12(36):iii, ix-x, 1-86. Review.
Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.
Nuijten MJ, Wittenberg W, Lebmeier M.
Pharmacoeconomics. 2007;25(1):55-71.
Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
Diehl JL, Daw JR, Coley KC, Rayburg R.
J Manag Care Pharm. 2010 Jan-Feb;16(1):23-31.
Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
Lofland JH, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, Desai SA.
Clin Ther. 2000 Nov;22(11):1357-69.
Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.
Pediatrics. 2004 Dec;114(6):1612-9.
Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR.
Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S46-54.
Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Reeve CA, Whitehall JS, Buettner PG, Norton R, Reeve DM, Francis F.
J Paediatr Child Health. 2006 May;42(5):253-8.
A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ.
J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. Review.
Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group.
Pediatr Infect Dis J. 2003 Sep;22(9):823-7.
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
Pediatrics. 2003 Dec;112(6 Pt 1):1442-6.
Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.
Nuijten M, Lebmeier M, Wittenberg W.
J Med Econ. 2009;12(4):291-300.
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
[No authors listed]
Pediatrics. 1998 Sep;102(3 Pt 1):531-7.
Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE, Mahle WT.
Pediatrics. 2004 Dec;114(6):1606-11.
Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA.
Pediatrics. 1999 Sep;104(3 Pt 1):419-27.
Palivizumab: new indication. Moderate reduction in hospitalisation rate.
Prescrire Int. 2004 Dec;13(74):213-6.
Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O.
Arch Dis Child Fetal Neonatal Ed. 2005 Jan;90(1):F64-8.
Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants.
Banerji A, Lanctôt KL, Paes BA, Masoud ST, Tam DY, Macdonald WA, Roberts A.
Pediatr Infect Dis J. 2009 Aug;28(8):702-6.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on